Results 161 to 170 of about 18,578 (279)

Real‐World Use of Rituximab in the Treatment of Cold Agglutinin Disease in the United States: A Retrospective Study

open access: yeseJHaem, Volume 6, Issue 4, August 2025.
ABSTRACT Introduction Rituximab is used off‐label for treating cold agglutinin disease (CAD) in the United States; however, real‐world data on its use are limited. Methods This study examined (1) treatment patterns, (2) prespecified safety outcomes, and (3) changes in hemolytic markers post rituximab infusion (threshold change from baseline: hemoglobin
Caroline Piatek   +10 more
wiley   +1 more source

SARM1 Exacerbates Pressure Overload‐Induced Cardiac Hypertrophy and Heart Failure by Enhancing NAD+ Metabolism

open access: yesThe FASEB Journal, Volume 39, Issue 14, 31 July 2025.
Under pathological conditions, elevated hydrolytic activity of SARM1 significantly depletes NAD+ levels and compromises electron transport chain (ETC) function. This disruption induces mitochondrial dysfunction, elevates ROS production, reduces ATP synthesis, and increases inflammation, which collectively accelerate cardiac hypertrophy (CH) and ...
Hui‐Ting Shi   +11 more
wiley   +1 more source

Monoclonal Gammopathy of Neurological Significance: A Case Report and Insights on Treatment. [PDF]

open access: yesMediterr J Hematol Infect Dis
Biglietto M   +7 more
europepmc   +1 more source

Advanced glycation end products promote the release of endothelial cell‐derived mitocytosis

open access: yesFEBS Open Bio, Volume 15, Issue 7, Page 1068-1078, July 2025.
Under diabetic conditions, AGEs induce mitochondrial damage in HUVECs, activating migrasome‐mediated mitocytosis. Migrasomes encapsulate damaged mitochondria and are released into the extracellular space, facilitating intercellular mitochondrial transfer.
Rong Liu   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy